Longevity Next

LongevityNext / Biomarkers

Biomarkers

Source-reviewed evidence, findings and limitations. Research intelligence, not treatment recommendations.

7 eligible records

Source-reviewed intelligence

Latest records

Automatically included source-reviewed records; inclusion is not an editorial endorsement.

Biomarker intelligence Source-reviewed

Short Physical Performance Battery

Evidence reviewed

Among older community-dwelling adults, poorer performance on the Short Physical Performance Battery, a set of balance, walking and chair-rise tests, was associated with higher mortality and nursing-home admission after adjustment for other factors. This was observational prediction, not a treatment comparison. It does not show that raising a person’s test score will prevent either outcome.

Boundary: Residual confounding and limited transportability; no clinically validated surrogate or treatment-guidance utility shown.

Biomarker intelligence Source-reviewed

Circulating taurine

Evidence reviewed

Circulating taurine is not supported as a universal, consistently declining marker of human aging.

Boundary: Age, activity, frailty and cohort context differ; association is not causation.

Biomarker intelligence Source-reviewed

DNAm GrimAge and GrimAge2

Evidence reviewed

GrimAge and GrimAge2 are distinct mortality-trained DNA methylation predictors with overlapping cohort lineage.

Boundary: Prediction does not establish treatment benefit; samples are not unique people.

Biomarker intelligence Source-reviewed

VO2max / cardiorespiratory fitness

Evidence reviewed

Cardiorespiratory fitness is prognostic; Generation 100 did not demonstrate a combined-exercise mortality advantage over active controls.

Boundary: VO2peak in this trial is not verified VO2max for everyone or a validated longevity surrogate.

Biomarker intelligence Source-reviewed

Gait speed

Evidence reviewed

Gait speed is prognostic; LIFE separately showed reduced loss of 400-m walking ability with structured physical activity.

Boundary: This does not validate every gait-speed change as a longevity surrogate.

Biomarker Intelligence Source-reviewed

Immune Age Signals

Evidence reviewed

Distinct immune-aging model families mapped as research-stage signals with explicit validation gaps.

Boundary: Not an approved diagnostic, consumer test, surrogate endpoint or clinical decision tool.

View all biomarker records

Source-reviewed intelligence

Section intelligence

Directly related records lead this section.

Biomarker Intelligence Source-reviewed

Composite Aging Biomarker Panel

Evidence reviewed

Research-stage DNA methylation age and pace-of-aging measures with bounded utility claims.

Boundary: Does not establish diagnosis, clinical utility or a definitive biological-age reading.

Regulation/Claims Watch Source-reviewed

Consumer Biomarker Claims Watch

Evidence reviewed

Regulatory claim-risk context for consumer biomarkers and direct-to-consumer tests.

Boundary: Not legal advice, biological evidence or a product-specific finding.

Source-reviewed intelligence

Related intelligence

Additional directly related records follow the section-specific lead set.

Company Intelligence Source-reviewed

BioAge Labs

Evidence reviewed

Company-and-pipeline intelligence separating company reports, registry facts and unavailable clinical outcomes.

Boundary: Pipeline and source mapping, not clinical validation or investment analysis.

LN Pro preview

Professional tracking and monitored workflows are presented as a bounded preview.

Request access
Opens in a new tab